PDTC enables type I TRAIL signaling in type II follicular lymphoma cells

Leukemia Research

Volumn 33, Issue 6, 2009, Pages 829-836

  Nuutinen, Ulla ^a   Simelius, Niina ^a   Ropponen, Antti ^a   Eeva, Jonna ^a   Mättö, Mikko ^a   Eray, Mine ^b   Pellinen, Riikka ^a   Wahlfors, Jarmo ^a   Pelkonen, Jukka ^a,c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Apoptosis; Bcl XL; Caspase 9; Follicular lymphoma; Human; Mitochondria; NF B; TRAIL

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; CASPASE 8; CASPASE 9; PROTEIN BCL XL; PROTEIN BID; PYRROLIDINE DITHIOCARBAMATE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; LYMPHOMA CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BCL-X PROTEIN; CASPASE 8; CELL LINE, TUMOR; DNA PRIMERS; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMANS; LYMPHOMA, FOLLICULAR; MUTAGENESIS, SITE-DIRECTED; NF-KAPPA B; PROLINE; SIGNAL TRANSDUCTION; THIOCARBAMATES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 63349101915     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.09.025     Document Type: Article

References (59)

1. Tsujimoto Y., Cossman J., Jaffe E., and Croce C.M. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228 (1985) 1440-1443
2. Freedman A., Friedberg J.W., and Gribben J. High-dose therapy for follicular lymphoma. Oncology (Williston Park) 14 (2000) 321-326 329; discussion 330-2, 338
3. Havell E.A., Fiers W., and North R.J. The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med 167 (1988) 1067-1085
4. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., et al. Lethal effect of the anti-Fas antibody in mice. Nature 364 (1993) 806-809
5. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104 (1999) 155-162
6. Held J., and Schulze-Osthoff K. Potential and caveats of TRAIL in cancer therapy. Drug Resist Updat 4 (2001) 243-252
7. Wajant H., Pfizenmaier K., and Scheurich P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 7 (2002) 449-459
8. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5 (1999) 157-163
9. Chaudhary P.M., Eby M., Jasmin A., Bookwalter A., Murray J., and Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 7 (1997) 821-830
10. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., et al. The receptor for the cytotoxic ligand TRAIL. Science 276 (1997) 111-113
11. Walczak H., Degli-Esposti M.A., Johnson R.S., Smolak P.J., Waugh J.Y., Boiani N., et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 16 (1997) 5386-5397
12. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273 (1998) 14363-14367
13. Marsters S.A., Sheridan J.P., Pitti R.M., Huang A., Skubatch M., Baldwin D., et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 7 (1997) 1003-1006
14. Pan G., Ni J., Wei Y.F., Yu G., Gentz R., and Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277 (1997) 815-818
15. Bodmer J.L., Holler N., Reynard S., Vinciguerra P., Schneider P., Juo P., et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2 (2000) 241-243
16. Kischkel F.C., Hellbardt S., Behrmann I., Germer M., Pawlita M., Krammer P.H., et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14 (1995) 5579-5588
17. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., and Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12 (2000) 611-620
18. Sprick M.R., Weigand M.A., Rieser E., Rauch C.T., Juo P., Blenis J., et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12 (2000) 599-609
19. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17 (1998) 1675-1687
20. Li H., Zhu H., Xu C.J., and Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94 (1998) 491-501
21. Luo X., Budihardjo I., Zou H., Slaughter C., and Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94 (1998) 481-490
22. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91 (1997) 479-489
23. Zou H., Henzel W.J., Liu X., Lutschg A., and Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90 (1997) 405-413
24. Srinivasula S.M., Ahmad M., Fernandes-Alnemri T., and Alnemri E.S. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1 (1998) 949-957
25. Zou H., Li Y., Liu X., and Wang X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 274 (1999) 11549-11556
26. Du C., Fang M., Li Y., Li L., and Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102 (2000) 33-42
27. Martins L.M., Iaccarino I., Tenev T., Gschmeissner S., Totty N.F., Lemoine N.R., et al. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem 277 (2002) 439-444
28. Suzuki Y., Imai Y., Nakayama H., Takahashi K., Takio K., and Takahashi R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell 8 (2001) 613-621
29. Verhagen A.M., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E., et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102 (2000) 43-53
30. Verhagen A.M., Silke J., Ekert P.G., Pakusch M., Kaufmann H., Connolly L.M., et al. HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J Biol Chem 277 (2002) 445-454
31. Daugas E., Susin S.A., Zamzami N., Ferri K.F., Irinopoulou T., Larochette N., et al. Mitochondria-nuclear translocation of AIF in apoptosis and necrosis. FASEB J 14 (2000) 729-739
32. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Snow B.E., Brothers G.M., et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397 (1999) 441-446
33. Li L.Y., Luo X., and Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 412 (2001) 95-99
34. Parrish J., Li L., Klotz K., Ledwich D., Wang X., and Xue D. Mitochondrial endonuclease G is important for apoptosis in C. elegans. Nature 412 (2001) 90-94
35. Ozoren N., and El-Deiry W.S. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 4 (2002) 551-557
36. Suliman A., Lam A., Datta R., and Srivastava R.K. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 20 (2001) 2122-2133
37. Rudner J., Jendrossek V., Lauber K., Daniel P.T., Wesselborg S., and Belka C. Type I and type II reactions in TRAIL-induced apoptosis-results from dose-response studies. Oncogene 24 (2005) 130-140
38. Eray M., Postila V., Eeva J., Ripatti A., Karjalainen-Lindsberg M.L., Knuutila S., et al. Follicular lymphoma cell lines, an in vitro model for antigenic selection and cytokine-mediated growth regulation of germinal centre B cells. Scand J Immunol 57 (2003) 545-555
39. Matto M., Nuutinen U.M., Ropponen A., Myllykangas K., and Pelkonen J. CD45RA and RO isoforms have distinct effects on cytokine- and B-cell-receptor-mediated signalling in human B cells. Scand J Immunol 61 (2005) 520-528
40. Nuutinen U., Postila V., Matto M., Eeva J., Ropponen A., Eray M., et al. Inhibition of PI3-kinase-Akt pathway enhances dexamethasone-induced apoptosis in a human follicular lymphoma cell line. Exp Cell Res 312 (2006) 322-330
41. Pellinen R., Hakkarainen T., Wahlfors T., Tulimaki K., Ketola A., Tenhunen A., et al. Cancer cells as targets for lentivirus-mediated gene transfer and gene therapy. Int J Oncol 25 (2004) 1753-1762
42. Fulda S., Meyer E., and Debatin K.M. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21 (2002) 2283-2294
43. Keogh S.A., Walczak H., Bouchier-Hayes L., and Martin S.J. Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis. FEBS Lett 471 (2000) 93-98
44. Kim E.J., Suliman A., Lam A., and Srivastava R.K. Failure of Bcl-2 to block mitochondrial dysfunction during TRAIL-induced apoptosis. Tumor necrosis-related apoptosis-inducing ligand. Int J Oncol 18 (2001) 187-194
45. Rudner J., Lepple-Wienhues A., Budach W., Berschauer J., Friedrich B., Wesselborg S., et al. Wild-type, mitochondrial and ER-restricted Bcl-2 inhibit DNA damage-induced apoptosis but do not affect death receptor-induced apoptosis. J Cell Sci 114 (2001) 4161-4172
46. Walczak H., Bouchon A., Stahl H., and Krammer P.H. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Res 60 (2000) 3051-3057
47. Hinz S., Trauzold A., Boenicke L., Sandberg C., Beckmann S., Bayer E., et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 19 (2000) 5477-5486
48. Munshi A., Pappas G., Honda T., McDonnell T.J., Younes A., Li Y., et al. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhabitable by Bcl-2. Oncogene 20 (2001) 3757-3765
49. Rokhlin O.W., Guseva N., Tagiyev A., Knudson C.M., and Cohen M.B. Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis. Oncogene 20 (2001) 2836-2843
50. Ruiz de Almodovar C., Ruiz-Ruiz C., Munoz-Pinedo C., Robledo G., and Lopez-Rivas A. The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels. Oncogene 20 (2001) 7128-7133
51. Srinivasula S.M., Datta P., Fan X.J., Fernandes-Alnemri T., Huang Z., and Alnemri E.S. Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway. J Biol Chem 275 (2000) 36152-36157
52. Sun S.Y., Yue P., Zhou J.Y., Wang Y., Choi Kim H.R., Lotan R., et al. Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem Biophys Res Commun 280 (2001) 788-797
53. Skommer J., Wlodkowic D., Matto M., Eray M., and Pelkonen J. HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells. Leuk Res 30 (2006) 322-331
54. Bossy-Wetzel E., Newmeyer D.D., and Green D.R. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J 17 (1998) 37-49
55. Waterhouse N.J., Goldstein J.C., von Ahsen O., Schuler M., Newmeyer D.D., and Green D.R. Cytochrome c maintains mitochondrial transmembrane potential and ATP generation after outer mitochondrial membrane permeabilization during the apoptotic process. J Cell Biol 153 (2001) 319-328
56. Samraj A.K., Keil E., Ueffing N., Schulze-Osthoff K., and Schmitz I. Loss of caspase-9 provides genetic evidence for the type I/II concept of CD95-mediated apoptosis. J Biol Chem 281 (2006) 29652-29659
57. Ozoren N., Kim K., Burns T.F., Dicker D.T., Moscioni A.D., and El-Deiry W.S. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 60 (2000) 6259-6265
58. Deng Y., Lin Y., and Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 16 (2002) 33-45
59. Nagy K., Szekely-Szuts K., Izeradjene K., Douglas L., Tillman M., Barti-Juhasz H., et al. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria. Pathol Oncol Res 12 (2006) 133-142